Systemic sclerosis

Czech version

Authors: M. Tomčík
Authors‘ workplace: Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
Published in: Kardiol Rev Int Med 2014, 16(5): 414-419
Category: Internal Medicine

Overview

Systemic sclerosis (SSc) is a rare, chronic connective tissue disease affecting the skin, musculoskeletal system and internal organs. SSc occurs predominantly in women, begins usually in middle age, and the overall survival rate is reduced – 70% of patients survive 10 years. Despite the advances in pharmacotherapy of organ complications and new insights into the pathogenesis of SSc, there is no effective treatment for this serious disorder. The aim of this review article is to introduce this rare disease, its main symptoms, basic principles of diagnosis and current treatment, and contribute to early diagnosis and better prognosis of patients with SSc.

Keywords:
systemic sclerosis – rheumatic diseases – connective tissue disease – fibrosis – vasculopathy – autoimmunity

Sources

1. Gabrielli A, Avvedimento EV, Krieg T. Mechanisms of Disease: Scleroderma. N Engl J Med 2009; 360: 1989– 2003. doi: 10.1056/ NEJMra0806188.

2. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581– 590.

3. Boin F, Rosen A. Autoimmunity in systemic sclerosis: current concepts. Curr Rheumatol Rep 2007; 9: 165– 172.

4. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010; 9: A311– A318. doi: 10.1016/ j.autrev.2009.11.003.

5. Chifflot H, Fautrel B, Sordet C et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37: 223– 235.

6. Feghali– Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48: 1956– 1963.

7. Mora GF. Systemic sclerosis: environmental factors. J Rheumatol 2009; 36: 2383– 2396. doi: 10.3899/ jrheum.090207.

8. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557– 567.

9. Kahaleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. J Exp Med 1979; 149: 1326– 1335.

10. Artlett CM. Immunology of systemic sclerosis. Front Biosci 2005; 10: 1707– 1719.

11. Bassel M, Hudson M, Taillefer SS et al. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology 2011; 50: 762– 767. doi: 10.1093/ rheumatology/ keq310.

12. Krieg T, Takehara K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology 2009; 48 (3 Suppl): 14– 18. doi: 10.1093/ rheumatology/ kep108.

13. Avouac J, Walker UA, Hachulla E et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2014; pii: annrheumdis– 2014– 205295. doi: 10.1136/ annrheumdis‑ 2014‑ 205295.

14. Gyger G, Baron M. Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep 2012; 14: 22– 29. doi: 10.1007/ s11926‑ 011‑ 0217‑ 3.

15. Hassoun PM. Lung involvement in systemic sclerosis. Presse med 2011; 40 (1 Pt 2): e3– e17. doi: 10.1016/ j.lpm.2010.08.006.

16. Parks JL, Taylor MH, Parks LP et al. Systemic sclerosis and the heart. Rheum Dis Clin North Am 2014; 40: 87– 102. doi: 10.1016/ j.rdc.2013.10.007.

17. Sabir O, Younas H, Tanvir I, Tarif N. Scleroderma renal crises: case report and review of literature. J Pak Med Assoc 2013; 63: 916– 918.

18. van den Hoogen F, Khanna D, Fransen J et al.2013 classification criteria for systemic sclerosis: an American college of rheumatology/ European league against rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747– 1755. doi: 10.1136/ annrheumdis‑ 2013‑ 204424.

19. Ingegnoli F, Gualtierotti R. A systematic overview on the use and relevance of capillaroscopy in systemic sclerosis. Expert Rev Clin Immunol 2013; 9: 1091– 1097. doi: 10.1586/ 1744666X.2013.849198.

20. Nashel J, Steen V. Scleroderma mimics. Curr Rheum Rep 2012; 14: 39– 46. doi: 10.1007/ s11926‑ 011‑ 0220‑ 8.

21. Avouac J, Kowal- Bielecka O, Landewe R et al. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis 2009; 68: 629– 634. doi: 10.1136/ ard.2008.095299.

22. Czirjak L, Kumanovics G, Varju C et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 59– 63.

23. Hissaria P, Lester S, Hakendorf P et al. Survival in scleroderma: results from the population‑based South Australian Register. Intern Med J 2011; 41: 381– 390. doi: 10.1111/ j.1445‑ 5994.2010.02281.x.

24. Nihtyanova SI, Tang EC, Coghlan JG et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010; 103: 109– 115. doi: 10.1093/ qjmed/ hcp174.

25. Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809– 1815. doi: 10.1136/ ard.2009.114264.